+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
CAR T-cell Therapy Market by Indication, Cell Source, Generation, Line Of Therapy, Target Antigen, End User - Global Forecast to 2030- Product Image
CAR T-cell Therapy Market by Indication, Cell Source, Generation, Line Of Therapy, Target Antigen, End User - Global Forecast to 2030- Product Image
Sale

CAR T-cell Therapy Market by Indication, Cell Source, Generation, Line Of Therapy, Target Antigen, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5924697
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The CAR T-cell Therapy Market grew from USD 4.51 billion in 2024 to USD 5.19 billion in 2025. It is expected to continue growing at a CAGR of 14.68%, reaching USD 10.27 billion by 2030.

Pioneering the Next Frontier in CAR T-cell Therapeutics

Chimeric antigen receptor T-cell therapy represents a paradigm shift in oncological treatment, harnessing the patient’s own immune cells to target and eradicate malignant cells with unparalleled precision. Over the past decade, this modality has transitioned from a conceptual breakthrough to a clinical reality, offering new hope for patients with hematologic malignancies who had exhausted conventional options. The convergence of genetic engineering, cell biology, and immunology has fostered innovative products that reprogram T lymphocytes to recognize tumor antigens, thereby catalyzing durable remissions in acute lymphoblastic leukemia and refractory lymphomas.

This study provides a holistic overview of the CAR T-cell ecosystem, mapping out scientific advancements, regulatory milestones, and market dynamics that collectively shape the next wave of immunotherapies. By examining the drivers behind rapid adoption, the barriers to broader accessibility, and the evolving competitive landscape, stakeholders can anticipate strategic inflection points and align investments with emerging opportunities. The findings presented here are grounded in rigorous primary and secondary research, offering a robust foundation for decision-makers eager to lead in this transformative field.

Rewriting Cancer Care Through Unprecedented Scientific Advancements

Recent years have witnessed an acceleration of technological innovations that have redefined the contours of CAR T-cell therapy. Breakthroughs in vector design and gene editing have enabled the creation of “armored” constructs that secrete cytokines or evade inhibitory microenvironments, thereby enhancing antitumor potency. Concurrently, the shift toward allogeneic, off-the-shelf products promises to alleviate manufacturing bottlenecks and reduce time to infusion, addressing critical challenges associated with autologous processing.

Advances in manufacturing automation, including closed-system bioreactors and digital process analytics, are streamlining supply chains and lowering production costs. Regulatory bodies have evolved frameworks to accommodate these complex therapies, approving novel indications and adaptive trial designs that expedite patient access. Collectively, these developments are rewriting the playbook for cellular immunotherapy, setting the stage for next-generation constructs that combine multiplexed antigen targeting with integrated safety switches.

Assessing the Strategic Fallout of 2025 US Tariff Measures

The introduction of new tariff schedules in the United States effective 2025 has injected complexity into the global CAR T-cell supply chain. Additional duties levied on critical reagents, viral vectors, and bioprocessing equipment have elevated manufacturing costs, prompting companies to explore cost containment strategies and renegotiate supplier agreements. This recalibration has intensified efforts to localize production and diversify procurement, mitigating exposure to cross-border tariffs and logistical delays.

Manufacturers are increasingly turning to domestic partners and establishing regional hubs to maintain stable supply and price predictability. While short-term margin pressures are evident, these measures foster long-term resilience and may catalyze strategic investments in decentralized manufacturing capabilities. Payers and healthcare systems are tracking these cost shifts closely, recalibrating reimbursement models to ensure sustainable adoption without compromising patient access.

Decoding Patient Population and Treatment Dynamics

Understanding patient populations and therapeutic nuances is essential for guiding clinical development and market access. Indication segmentation reveals that leukemia remains a cornerstone for CAR T-cell applications, with acute lymphoblastic leukemia commanding significant research focus due to its high unmet need. Acute myeloid leukemia, while more heterogeneous, is gaining traction through novel target discovery. Multiple myeloma has emerged as a fertile domain for BCMA-directed therapies, driven by encouraging remission rates in heavily pretreated cohorts. In the realm of non-Hodgkin lymphoma, diffuse large B-cell lymphoma serves as the primary entry point, followed by follicular and mantle cell lymphoma, each presenting unique microenvironmental challenges and response profiles.

Cell source segmentation underscores the dominance of autologous approaches but highlights a rising interest in allogeneic platforms that promise streamlined logistics. Generation segmentation confirms the prevalence of second-generation constructs in the clinic, yet it also spotlights burgeoning pipelines in third and fourth generations, which integrate multiantigen targeting and built-in regulatory elements. Line of therapy insights show that relapsed and refractory patients continue to drive initial approvals, while frontline indications are actively being pursued to expand treatment paradigms. Target antigen dynamics indicate that CD19 remains a foundational focus, with BCMA rapidly ascending in myeloma. End user segmentation illustrates that hospitals and outpatient oncology centers deliver the bulk of therapies, academic research institutes serve as innovation incubators, and specialty clinics facilitate niche or early-phase trials.

Navigating Regional Markets and Adoption Drivers

Regional analysis reveals a highly differentiated landscape shaped by regulatory, economic, and healthcare infrastructure variables. In the Americas, established reimbursement frameworks and robust clinical trial networks underpin rapid uptake, with the United States at the forefront of both approval and commercialization. Europe, the Middle East, and Africa present a mosaic of market access challenges and opportunities, as evolving health technology assessment processes in Western Europe contrast with developing reimbursement pathways in emerging markets.

Asia-Pacific stands as a growth engine, propelled by government-backed initiatives, local manufacturing incentives, and burgeoning clinical research in China, Japan, South Korea, and Australia. Cross-border collaborations are on the rise, with technology transfers and joint ventures enabling regional hubs to serve both domestic and export markets. This regional diversity necessitates tailored strategies for regulatory engagement, pricing, and distribution to optimize patient outreach and commercial performance.

Illuminating the Competitive Horizon in Cell Therapy

The competitive arena of CAR T-cell therapy is defined by a blend of established pharmaceutical giants, agile biotech innovators, and academic spin-offs. Pioneering approvals such as those from major US biopharma firms laid the groundwork for blockbuster applications in hematologic malignancies. Today, an influx of midsized players and specialized cell therapy companies is intensifying pipeline competition, with differentiated platforms targeting novel antigens and employing next-generation gene editing.

Strategic alliances are proliferating, as large corporations seek external innovation to augment internal R&D, while smaller entities gain access to scale and commercialization expertise. Licensing agreements, co-development partnerships, and collaborative manufacturing ventures are reshaping the landscape, fostering an ecosystem where collaboration and competition coexist. Intellectual property portfolios and proprietary manufacturing processes will serve as critical differentiators as new entrants vie for market share.

Charting a Purpose-Driven Roadmap for Strategic Growth

Industry leaders must adopt a multifaceted strategy to capitalize on the evolving CAR T-cell market. Firstly, expanding allogeneic and multiantigen pipelines will address unmet needs and create differentiation. Secondly, investing in advanced manufacturing platforms-such as localized, modular facilities-will fortify supply chain resilience and control cost escalation driven by tariffs or geopolitical shifts. Thirdly, proactive engagement with regulatory agencies to shape adaptive approval pathways will accelerate time to market while ensuring safety and efficacy standards.

In parallel, forging strategic partnerships with academic centers and contract development organizations will accelerate innovation and enhance operational capacity. Market access functions should refine value demonstration frameworks, leveraging real-world evidence to support reimbursement negotiations. Finally, cultivating a robust patient and caregiver support ecosystem will facilitate therapy uptake and adherence, thereby reinforcing long-term outcomes and payer confidence.

Ensuring Rigor Through Integrated Research Methodologies

This analysis integrates primary research-comprising in-depth interviews with key opinion leaders, clinical investigators, and senior executives-with secondary sources, including peer-reviewed literature, regulatory filings, and annual reports. Data triangulation techniques were employed to validate market trends and competitive dynamics, while proprietary databases informed insight into clinical trial activity and patent landscapes.

Rigorous quality control protocols ensured methodological consistency, and confidentiality agreements safeguarded the integrity of sensitive information. Workshops with industry experts provided iterative feedback on emerging themes, guaranteeing that final conclusions reflect both quantitative metrics and real-world perspectives. This robust approach underpins the credibility and relevance of the findings presented herein.

Unifying Insights to Propel the CAR T-cell Ecosystem Forward

CAR T-cell therapy has evolved from an experimental immunotherapy to a central pillar of modern oncology, underscored by transformative clinical outcomes and a dynamic competitive landscape. The interwoven complexities of indication-specific challenges, cell source innovations, and advanced construct generations demand nuanced strategies for development and commercialization. Furthermore, emerging tariff policies and regional heterogeneity necessitate adaptive supply chain and market access frameworks.

By synthesizing segmentation insights, regional dynamics, and competitive trends, this study equips stakeholders with the knowledge to navigate uncertainties and seize growth opportunities. As the field continues to expand into new indications and indications shift toward earlier lines of therapy, proactive leadership and strategic collaboration will be pivotal in delivering on the full promise of CAR T-cell therapeutics.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Indication
    • Leukemia
      • Acute Lymphoblastic Leukemia
      • Acute Myeloid Leukemia
    • Multiple Myeloma
    • Non Hodgkin Lymphoma
      • Diffuse Large B Cell Lymphoma
      • Follicular Lymphoma
      • Mantle Cell Lymphoma
  • Cell Source
    • Allogeneic
    • Autologous
  • Generation
    • First Generation
    • Fourth Generation
    • Second Generation
    • Third Generation
  • Line Of Therapy
    • Frontline
    • Relapsed Refractory
  • Target Antigen
    • BCMA
    • CD19
  • End User
    • Academic Research Institutes
    • Hospitals
    • Outpatient Oncology Centers
    • Specialty Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Legend Biotech Corporation
  • Miltenyi Biotec GmbH
  • Allogene Therapeutics, Inc.
  • Cellectis S.A.
  • Autolus Therapeutics plc
  • Poseida Therapeutics, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. CAR T-cell Therapy Market, by Indication
8.1. Introduction
8.2. Leukemia
8.2.1. Acute Lymphoblastic Leukemia
8.2.2. Acute Myeloid Leukemia
8.3. Multiple Myeloma
8.4. Non Hodgkin Lymphoma
8.4.1. Diffuse Large B Cell Lymphoma
8.4.2. Follicular Lymphoma
8.4.3. Mantle Cell Lymphoma
9. CAR T-cell Therapy Market, by Cell Source
9.1. Introduction
9.2. Allogeneic
9.3. Autologous
10. CAR T-cell Therapy Market, by Generation
10.1. Introduction
10.2. First Generation
10.3. Fourth Generation
10.4. Second Generation
10.5. Third Generation
11. CAR T-cell Therapy Market, by Line Of Therapy
11.1. Introduction
11.2. Frontline
11.3. Relapsed Refractory
12. CAR T-cell Therapy Market, by Target Antigen
12.1. Introduction
12.2. BCMA
12.3. CD19
13. CAR T-cell Therapy Market, by End User
13.1. Introduction
13.2. Academic Research Institutes
13.3. Hospitals
13.4. Outpatient Oncology Centers
13.5. Specialty Clinics
14. Americas CAR T-cell Therapy Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa CAR T-cell Therapy Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific CAR T-cell Therapy Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Novartis AG
17.3.2. Gilead Sciences, Inc.
17.3.3. Bristol-Myers Squibb Company
17.3.4. Johnson & Johnson
17.3.5. Legend Biotech Corporation
17.3.6. Miltenyi Biotec GmbH
17.3.7. Allogene Therapeutics, Inc.
17.3.8. Cellectis S.A.
17.3.9. Autolus Therapeutics plc
17.3.10. Poseida Therapeutics, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. CAR T-CELL THERAPY MARKET MULTI-CURRENCY
FIGURE 2. CAR T-CELL THERAPY MARKET MULTI-LANGUAGE
FIGURE 3. CAR T-CELL THERAPY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CAR T-CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. CAR T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. CAR T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CAR T-CELL THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CAR T-CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY DIFFUSE LARGE B CELL LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FRONTLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY RELAPSED REFRACTORY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY BCMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CD19, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY OUTPATIENT ONCOLOGY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 54. CANADA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 55. CANADA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 56. CANADA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 57. CANADA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 58. CANADA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 59. CANADA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 60. CANADA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 61. CANADA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. MEXICO CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 63. MEXICO CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 64. MEXICO CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 65. MEXICO CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 66. MEXICO CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 67. MEXICO CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 68. MEXICO CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 69. MEXICO CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. GERMANY CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. GERMANY CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 105. GERMANY CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 106. GERMANY CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 107. GERMANY CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 108. GERMANY CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 109. GERMANY CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 110. GERMANY CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. FRANCE CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 112. FRANCE CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 113. FRANCE CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 114. FRANCE CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 115. FRANCE CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 116. FRANCE CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 117. FRANCE CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 118. FRANCE CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. ITALY CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 128. ITALY CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 129. ITALY CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 130. ITALY CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 131. ITALY CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 132. ITALY CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 133. ITALY CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 134. ITALY CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. SPAIN CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 136. SPAIN CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 137. SPAIN CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 138. SPAIN CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 139. SPAIN CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 140. SPAIN CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 141. SPAIN CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 142. SPAIN CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. DENMARK CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 168. DENMARK CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 169. DENMARK CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 170. DENMARK CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 171. DENMARK CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 172. DENMARK CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 173. DENMARK CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 174. DENMARK CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. QATAR CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 184. QATAR CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 185. QATAR CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 186. QATAR CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 187. QATAR CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 188. QATAR CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 189. QATAR CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 190. QATAR CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. FINLAND CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 192. FINLAND CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 193. FINLAND CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 194. FINLAND CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 195. FINLAND CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 196. FINLAND CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 197. FINLAND CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 198. FINLAND CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. EGYPT CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 216. EGYPT CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 217. EGYPT CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 218. EGYPT CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 219. EGYPT CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 220. EGYPT CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 221. EGYPT CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 222. EGYPT CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. TURKEY CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 224. TURKEY CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 225. TURKEY CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 226. TURKEY CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 227. TURKEY CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 228. TURKEY CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 229. TURKEY CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 230. TURKEY CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. ISRAEL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. NORWAY CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 240. NORWAY CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 241. NORWAY CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 242. NORWAY CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 243. NORWAY CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 244. NORWAY CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 245. NORWAY CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 246. NORWAY CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. POLAND CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 248. POLAND CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 249. POLAND CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 250. POLAND CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 251. POLAND CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 252. POLAND CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 253. POLAND CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 254. POLAND CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 272. CHINA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 273. CHINA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 274. CHINA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 275. CHINA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 276. CHINA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 277. CHINA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 278. CHINA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 279. CHINA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. INDIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 281. INDIA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 282. INDIA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 283. INDIA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 284. INDIA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 285. INDIA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 286. INDIA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 287. INDIA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. JAPAN CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 289. JAPAN CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 290. JAPAN CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 291. JAPAN CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 292. JAPAN CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 293. JAPAN CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 294. JAPAN CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 295. JAPAN CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 296. AUSTRALIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 297. AUSTRALIA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 303. AUSTRALIA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 304. SOUTH KOREA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 305. SOUTH KOREA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 306. SOUTH KOREA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 311. SOUTH KOREA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 312. INDONESIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 313. INDONESIA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 314. INDONESIA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 315. INDONESIA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 318. INDONESIA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 319. INDONESIA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 320. THAILAND CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 321. THAILAND CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 322. THAILAND CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 323. THAILAND CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 324. THAILAND CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 325. THAILAND CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 326. THAILAND CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 327. THAILAND CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 328. PHILIPPINES CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 329. PHILIPPINES CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 330. PHILIPPINES CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 331. PHILIPPINES CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 332. PHILIPPINES CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 333. PHILIPPINES CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 334. PHILIPPINES CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 335. PHILIPPINES CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 336. MALAYSIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 337. MALAYSIA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 338. MALAYSIA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 339. MALAYSIA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 340. MALAYSIA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 341. MALAYSIA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 342. MALAYSIA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2030 (USD MILLION)
TABLE 343. MALAYSIA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 344. SINGAPORE CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 345. SINGAPORE CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 346. SINGAPORE CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 347. SINGAPORE CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 348. SINGAPORE CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2030 (USD MILLION)
TABLE 349. SINGAPORE CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 350. SINGAPORE

Companies Mentioned

The companies profiled in this CAR T-cell Therapy market report include:
  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Legend Biotech Corporation
  • Miltenyi Biotec GmbH
  • Allogene Therapeutics, Inc.
  • Cellectis S.A.
  • Autolus Therapeutics plc
  • Poseida Therapeutics, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages197
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 5.19 Billion
Forecasted Market Value ( USD ) by 2030 $ 10.27 Billion
Compound Annual Growth Rate14.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

T-Cell Immunotherapy Market by Therapy Type, Cell Source, Target Antigens, Manufacturing Method, Patient Type, Indication, End-User - Global Forecast to 2030 - Product Image

T-Cell Immunotherapy Market by Therapy Type, Cell Source, Target Antigens, Manufacturing Method, Patient Type, Indication, End-User - Global Forecast to 2030

  • Report
  • 190 Pages
  • Global
From
T-Cell Therapy Market by End User, Cell Source, Indication, Therapy Type, Manufacturing Model - Global Forecast to 2030 - Product Image

T-Cell Therapy Market by End User, Cell Source, Indication, Therapy Type, Manufacturing Model - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
CAR-T Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

CAR-T Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 182 Pages
  • Global
From
CAR T-cell Therapy - Global Strategic Business Report - Product Image

CAR T-cell Therapy - Global Strategic Business Report

  • Report
  • 179 Pages
  • Global
From
T-cell Therapy Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application - Product Image

T-cell Therapy Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application

  • Report
  • 79 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.